BioMedicine Designs Endogenous Antibody Discovery Group is seeking a Senior Scientist to expand and diversify lead panels of antibodies for biotherapeutic development. The candidate will be primarily responsible for carrying out microfluidics-based selections of B cells, as well as designing and implementing strategies to thoroughly interrogate rodent antibody repertoires (both paired and single chain) analyzed by Next Generation Sequencing and other DNA sequencing methods. In addition, the candidate will analyze the datasets employing established bioinformatics workflows to identify additional antibody candidates with optimized properties. The role also requires identification and application of new technologies and workflows to support our ongoing commitment to enhance and streamline discovery of lead therapeutic antibody clones. The candidate will work in collaboration with BioMedicine Designs High Throughput Assay Screening group as well as colleagues in BioMedicine Designs Bioinformatics and Antibody Structure groups. The successful candidate will have a demonstrated track record in some of the following areas:
* Microfluidics-based selection of B cells from immunized rodents.
* Generation of antibody libraries for Next Generation Sequencing.
* Antibody repertoire analysis, both paired and single chain, using NGS datasets.
* Knowledge of mouse B cell biology and familiarity with B cell lineage analysis desirable.
* Ability to code using Python; additional familiarity with R desirable.
* Working knowledge of antibody structure and antibody engineering desirable.
* Conversant with machine learning including neural network analysis as it applies to antibody repertoire and sequence analysis/optimization.
ROLE RESPONSIBILITIES
* Apply microfluidics-based methods to select antigen-specific B cells
* Generate paired and single-chain immune libraries from B cell populations for Next Generation Sequencing.
* Analyze and report on paired and single chain immune repertoires from Next Generation Sequencing data sets.
* Apply NGS-based methods to analyze B cell repertoires and to optimize lead antibody candidates.
* Scout out, propose, learn and implement new technologies to increase diversity of lead antibody panels.
* Prepare and deliver detailed presentations and reports, both written and verbal, to project teams.
* Communicate and coordinate work effectively in highly matrixed project team environment.
QUALIFICATIONS
Must have
* PhD in Molecular Immunology, Microfluidics, Next Generation Sequencing or related field.
* Hands-on experience working with primary B cells.
* Generation of antibody libraries for Next Generation Sequencing.
* Antibody repertoire analysis, both paired and single chain, using NGS datasets.
* Ability to generate graphical representation of antibody repertoires to aid data visualization.
* Excellent written and oral communication skills.
Nice to have
* 2 3 years of post-doctoral experience.
* Hands-on experience with microfluidics workflows, preferably with immune cells.
* Ability to code using Python.
* Knowledge of mouse B cell biology and familiarity with B cell lineage analysis.
* Conversant with machine learning including neural network analysis as it applies to antibody repertoire and sequence analysis/optimization.
PHYSICAL/MENTAL REQUIREMENTS
* Lifting, sitting, standing, walking, bending, ability to perform mathematical calculations.
* Ability to perform complex data analysis.
* Ability to code.
Other Job Details:
* Eligible for Relocation Package: YES
* Eligible for Employee Referral Bonus: YES
LI-PFE
Sunshine Act
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care providers name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.
Research and Development
LI-PFE
New York, New York
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names.
Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.